TPM
CRL icon

Triasima Portfolio Management’s Charles River Laboratories CRL Stock Holding History

Triasima Portfolio Management’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-775
Closed -$292K – 156
2021
Q4 		$292K Sell
775
-6,295
-89% -$2.45M 0.01% 147
2021
Q3 		$2.92M Buy
7,070
+5,485
+346% +$2.28M 0.16% 77
2021
Q2 		$586K Buy
1,585
+870
+122% +$291K 0.03% 137
2021
Q1 		$207K Buy
+715
New +$199K 0.01% 170

Other funds holding CRL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Triasima Portfolio Management's CRL Position: Q1 2022 in Review

Triasima Portfolio Management sold out of Charles River Laboratories (CRL) in Q1 2022, closing a stake of 775 shares — an estimated $292K sold.

Triasima Portfolio Management first reported a position in CRL in Q1 2021 and held it in 4 quarters. The position peaked at $2.92M in Q3 2021. 644 funds tracked by Wall St. Rank hold CRL as of Q1 2022.

  • Triasima Portfolio Management reported no remaining Charles River Laboratories position as of Q1 2022 after selling out during the quarter.
  • Triasima Portfolio Management sold 775 Charles River Laboratories shares in Q1 2022, an estimated $292K.
  • Triasima Portfolio Management first reported a position in Charles River Laboratories in Q1 2021 and held it in 4 quarters.
  • Triasima Portfolio Management's Charles River Laboratories position peaked at $2.92M in Q3 2021.
  • 644 funds tracked by Wall St. Rank held Charles River Laboratories as of Q1 2022.

Based on Triasima Portfolio Management's 13F filing for Q1 2022, filed 20 Jul 2022.